Market Newsdesk

FC Cincinnati Standardizes on Aruba at TQL Stadium to Deliver Next-Generation Digital, Cashless, Contactless Fan and Event Experiences

New Half a Million-Square-Foot Venue Relies Upon an Aruba ESP Network to Power Massive LED Video Systems, Mobility-Driven Fan Experiences and Other Amenities

SAN JOSE, Calif.–(BUSINESS WIRE)–
Aruba, a Hewlett Packard Enterprise company (NYSE: HPE), today announced that FC Cincinnati (FCC), the Cincinnati-based Major League Soccer (MLS) franchise, has deployed an end-to-end Aruba ESP (Edge Services Platform) network at its new 26,000-seat TQL Stadium to power one of the most ambitious soccer-specific venues worldwide, raising the bar for game day and special event experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005267/en/

To create its completely cashless, digitalized facility, FCC deployed a combination of Aruba’s wired, wireless and security solutions. Visitor-facing connectivity starts with SeatGeek mobile ticketing and Fortress wireless scanners for fast, paperless entry. For game and other visuals, two massive Daktronics and 14,370 feet of SACO V-STICK S display live images, instant replays, up-to-the-minute statistics, graphics and animations inside the stadium and across the building’s expansive eastern façade.

Operational connectivity includes approximately 200 point-of-sale devices controlled by cloud-enabled Appetize to support the stadium’s 175 food and beverage vendors, enabling FCC to process thousands of game day and special event transactions within milliseconds. Other connected systems range from hundreds of security cameras and door access devices to multiple business applications such as Microsoft Office 365.

“We based every aspect of designing, building and maintaining our stadium on creating next-generation fan experiences,” explained Dan Lolli, vice president of Facilities and Stadium General Manager for FC Cincinnati. “Working with our IT-as-a-Service partner Atomic Data, we determined Aruba was the leader in stadium deployments that provide fans with superior, high-performance, reliable, and consistent experiences while being efficient and cost-effective to manage.”

In collaboration with Atomic Data, FCC selected and deployed a future-ready wireless network comprised of Aruba’s Wi-Fi 6 indoor and outdoor access points (APs) and mobility controllers. For wired networking, FCC implemented Aruba’s access switches at the edge for IP audio and video along with the CX Series switches for access, aggregation and in the data center.

Deploying high-performance Wi-Fi enabled FCC to offer fans the latest in mobile amenities, such as the ability to deliver tickets to guests with the touch of a screen. “Mobile ticketing is also important from a business perspective as it eliminates much of the counterfeit ticketing that is widespread throughout entertainment,” said Lolli.

Once inside, guests enjoy contactless ordering of refreshments and merchandise to ensure they see all the action. “On opening day, our network processed more than 16,000 food and beverage transactions over a few hours, with most completed in less than half a second,” Lolli said. “Our network enables us to provide the exceptional experiences that help us differentiate ourselves from other sporting and non-sporting entertainment options.”

FCC is also relying on Aruba’s advanced network administration tools like ClearPass, for policy-based network access control (NAC) and NetEdit, for coordinating switch configuration, monitoring and troubleshooting. “During stadium construction, Aruba’s robust tools enabled Atomic Data to stage our entire network off-site and ship it to our stadium,” said Lolli. “This streamlined deployment by four to eight weeks versus the traditional on-site approach, helping us meet our Opening Day deadlines. Since then, Aruba’s software automation has ensured efficient network management on a day-to-day basis.”

Moving forward, FCC expects to continue evaluating Aruba’s cloud-based, AIOps-enabled networking innovations such as Aruba Central for proactive network management, User Experience Insight (UXI) for detecting Wi-Fi incidents that require immediate attention, and Air Pass for seamless device handoffs between cellular networks and Wi-Fi.

The team is also assessing Aruba’s Location Services for supporting real-time crowd intelligence. “As soccer fans only leave their seats during halftime, location services can help us with analyzing and directing traffic flow,” Lolli said. “Clearly, anything that assists with expanding opportunities for fans to have great experiences is something we’ll consider.”

About TQL Stadium

TQL Stadium, FC Cincinnati’s home, is one of the most ambitious soccer-specific stadiums in not only North America but the world. Critically acclaimed global design firm, Populous, designed an innovative and forward-thinking stadium that is one of the largest soccer-specific facilities in Major League Soccer (MLS). The $250 million, privately funded stadium has a capacity of 26,000, with the closest seats within 15 feet of the field. The design includes 53 traditional suites and 4,500 premium seats throughout four premium club spaces. Additionally, the team’s famous supporters’ section, The Bailey, will grow to be more than 3,100 strong and loom over opponents at a 34-degree angle at the stadium’s north end. A 360-degree canopy roof covers every seat in the stadium, but still allows sufficient sun in to grow a natural grass field. The stadium has five team locker rooms, including a comprehensive team suite for FC Cincinnati that features a dressing room, coaches offices, lounge, equipment storage and the Mercy Health Center of Excellence for the team’s medical and game day fitness needs. TQL Stadium meets all current requirements to host CONCACAF and FIFA events, featuring top national teams from around the world, including the U.S. Men’s and Women’s National Teams, as well as the world’s top club teams for friendlies. More information about the stadium is available at Twitter, Instagram and Facebook, or visit the stadium’s website: TQLStadium.com.

About Aruba, a Hewlett Packard Enterprise company

Aruba, a Hewlett Packard Enterprise company, is the global leader in secure, intelligent edge-to-cloud networking solutions that use AI to automate the network, while harnessing data to drive powerful business outcomes. With Aruba ESP (Edge Services Platform) and as-a-service options, Aruba takes a cloud-native approach to helping customers meet their connectivity, security, and financial requirements across campus, branch, data center, and remote worker environments, covering all aspects of wired, wireless LAN, and wide area networking (WAN).

To learn more, visit Aruba at www.arubanetworks.com. For real-time news updates, follow Aruba on Twitter and Facebook, and for the latest technical discussions on mobility and Aruba products, visit the Airheads Community at community.arubanetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005267/en/

Kathleen Keith

Aruba, a Hewlett Packard Enterprise company

+1-707-529-4507

[email protected]

Jennifer Miu

Aruba, a Hewlett Packard Enterprise company

+1 650-236-9532

[email protected]

KEYWORDS: United States North America California Ohio

INDUSTRY KEYWORDS: Software Sports Mobile/Wireless Networks Internet General Sports Hardware Data Management Technology Security Soccer Audio/Video Other Technology

MEDIA:

Logo

Photo

TQL Stadium, FC Cincinnati’s new half a million-square-foot venue, relies on Aruba ESP to drive next-generation, mobility-driven fan experiences. (Photo: FC Cincinnati)

Photo

FC Cincinnati has deployed Aruba ESP at its new 26,000-seat TQL Stadium. (Photo: FC Cincinnati)

Helbiz Announces Sponsorship of First Switzerland Electric Boat Ceremony

NEW YORK–(BUSINESS WIRE)–Helbiz Inc. (NASDAQ: HLBZ), a global leader in micro-mobility and the first in its industry to be publicly listed on Nasdaq, today announced its role as a Gold Sponsor of MNE Ceresio 1931, the first electric boat ceremony in Lugano, Switzerland. This event is part of the larger 20-35 Project, an initiative that is encouraging the conversion of fossil fuel propulsion to electric propulsion among all boats in the fleet of the Società Navigazione del Lago di Lugano by 2035.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005630/en/

The project kicked off yesterday with the inauguration of Switzerland’s first fully electric boat, designed with lake navigation to significantly reduce CO2 emissions. Helbiz was present in Lugano with its sustainable electric vehicles on display, offering its transportation services and recharging stations for guests to experience firsthand. The company also arranged safety demonstrations and test drives of its vehicles to promote the responsible use of scooters.

The event also marked the official debut of the Helbiz E-Station, a smart platform for renting, releasing and recharging electric scooters, now present in Lugano. The station can be moved to strategic points around the city to improve circulation flows and reduce carbon emissions.

“Helbiz is committed to raising awareness on key societal issues such as the reduction of CO2 and combating pollution,” said Giulio Profumo, Chief Financial Officer at Helbiz. “This event and the ongoing 20-35 project highlight the importance of pairing new technology with sustainable transportation. We are proud to be a sponsor of MNE Ceresio 1931, as it reflects the core values of Helbiz and underscores our respect for the environment.”

Helbiz plans to expand its micro-mobility services beyond the Alps in the near future.

About Helbiz

Helbiz is a global leader in micro-mobility services. Launched in 2015 and headquartered in New York City, the company offers a diverse fleet of vehicles including e-scooters, e-bicycles and e-mopeds all on one convenient, user-friendly platform in 35 cities around the world. Helbiz utilizes a customized, proprietary fleet management technology, artificial intelligence and environmental mapping to optimize operations and business sustainability. Helbiz is expanding its urban lifestyle products and services to include live streaming services, food delivery, financial services and more, all accessible within its mobile app.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and production targets; (ii) changes in applicable laws or regulations;(iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its periodic filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and amended on May 21, 2021. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Helbiz and speaks only as of the date on which it is made. Helbiz undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005630/en/

Helbiz Contacts

For investor and media inquiries, contact: https://www.helbiz.com/pressroom

Global Head of Communications: +1 ‎(917) 675-7157

Davide D’Amico – email: [email protected]

PR and Communication Manager:

Chiara Garbuglia – email: [email protected]

USA

Agent of Change

Marcy Simon – Phone: +1 (917) 833-3392 – email: [email protected]

The Blueshirt Group

Gary Dvorchak, CFA – Phone: +1 (323) 240-5796 – email: [email protected]

KEYWORDS: Europe Switzerland United States North America New York

INDUSTRY KEYWORDS: Electronic Design Automation Alternative Vehicles/Fuels Transportation Technology Automotive Travel Other Transport Maritime Automotive Manufacturing Transport Other Technology Manufacturing

MEDIA:

Logo

Photo

Helbiz Announces Sponsorship of First Switzerland Electric Boat Ceremony (Photo: Business Wire)

PhaseBio Appoints William D. Humphries to Board of Directors

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as director, effective immediately.

“Bill’s deep commercial expertise gained through his leadership roles at numerous specialty pharmaceutical companies will be an invaluable addition to our already robust board of directors,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “Bill joins us at an exciting and pivotal time in PhaseBio’s growth, as we continue to advance our clinical programs and begin to build a commercial organization to prepare to market bentracimab in the United States should it be approved.”

Mr. Mow added, “I would also like to thank Justin for his many contributions during his time as a director. He has proved himself to be a trusted advisor, who has been instrumental in helping PhaseBio get to where it is today, and continues to be one of the strongest champions of our mission.”

Mr. Humphries has more than 30 years of experience building and leading commercial-stage pharmaceutical organizations. He is currently the Chief Executive Officer of Isosceles Pharmaceuticals, a position he has held since May 2021. Prior to his role at Isosceles, Mr. Humphries served as President of Ortho Dermatologics, a Bausch Health Company. Before joining Ortho Dermatologics, he served as President and Chief Executive Officer of the North American business of Merz, an affiliate of Merz Pharma Group, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served in a number of leadership positions with Stiefel Laboratories, including as its Chief Commercial Officer and then as President, where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Earlier in his career Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, concluding as vice president of its U.S. skincare business.

In addition to joining the PhaseBio board of directors, Mr. Humphries currently serves as the chairman of the board for Clearside Biomedical, chairman of the board for STRATA Skin Sciences, and as a director on the board of Aclaris Therapeutics. He received a B.A. from Bucknell University and an M.B.A. from Pepperdine University.

“Having worked in commercially-focused roles in the pharmaceutical industry for much of my career, I am very passionate about bringing potentially life-changing medicines to the market and am thrilled to join the PhaseBio board at this critical juncture in the company’s evolution,” said Mr. Humphries. “I look forward to helping guide the building of the company’s U.S. commercial organization and charting an exciting path forward for the company as we advance our mission of developing medicines to address key unmet needs for people with cardiopulmonary disease.”

In addition to joining the PhaseBio board, Mr. Humphries was also appointed as a member of its compensation committee.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “potential,” “projects,” “target,” “will,” “would” and “future” or similar expressions are intended to identify forward-looking statements.

Forward-looking statements include statements concerning or implying the conduct or timing of our clinical trials and the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005251/en/

Investor Contact:

John Sharp

PhaseBio Pharmaceuticals, Inc.

Chief Financial Officer

(610) 981-6506

[email protected]

Media Contact:

Will Zasadny

Canale Communications, Inc.

(619) 961-8848

[email protected]

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Cardiology

MEDIA:

Logo

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–
Regulatory News:

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021.

“During the first half of 2021, we remained focused on advancing the development of our therapeutic programs. As announced in early 2021, our ALS-4 program (targeting infections caused by Staphylococcus aureus including MRSA) commenced a Phase 1 clinical study in Canada. We are pleased that 5 total cohorts, which represent the essential part of the single ascending dose (“SAD”) portion of the trial, have been completed without any serious adverse events being observed. On the basis of ALS-4’s favourable safety profile, we are commencing the multiple ascending dose (“MAD”) portion of the trial in Q3, 2021. Our other lead program SACT-1 (targeting neuroblastoma), has also received clearance from the US FDA to commence clinical trials in the United States. SACT-1 will be our second therapeutic program entering into the clinical phase. Our RPIDD program (liquid biopsy based approach to infectious disease rapid diagnostics) is also progressing well and we are very pleased to continue its clinical validation currently in collaboration with A*Star. Finally, we are excited to continue with our efforts of commercialising our NativusWell^® DOI product, a novel supplement targeting woman’s health including menopausal symptoms. We are also excited to continue to identify and progress on certain other potential novel therapeutic candidates, including our ongoing assessment of a number of novel immunomodulators developed by Yale University targeting major autoimmune diseases, as we announced earlier in the year,” said Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group Limited.

Clinical Pipeline Update and Upcoming Milestones

In September 2021, Aptorum Group received clearance from the US FDA to open an IND to conduct clinical trials on SACT-1, an orally administered small molecule repurposed drug for the treatment of neuroblastoma. The IND-opening study is a bioavailability/Food Effect study, followed by a Phase 1b/2a trial in neuroblastoma patients which is subject to further FDA approval.

In May 2021, Aptorum Group announced its ongoing Phase I clinical trial for one of its lead programs, ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including MRSA, under which two initial cohorts of the SAD portion of the trial in healthy male and female adult subjects have been completed with no serious adverse events observed. In July 2021, the Company further announced two additional cohorts (Cohort C & D) of the SAD portion have been completed with no serious adverse events observed. In total, up to 6 cohorts for SAD and 3 cohorts for MAD have been planned. The MAD study is commencing in Q3, 2021.

In May 2021, Aptorum Group entered into an agreement with Exeltis regarding Aptorum’s preclinical asset targeting women’s health and gynaecological conditions, including endometriosis, in the European Union and Latin America. Aptorum retained development rights in the rest of the world.

In April 2021, Aptorum Group entered into a material transfer and license option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators that could represent first-in-class therapeutics in treating autoimmune and oncology diseases, among other indications.

Corporate Highlights

In May 2021, Jurchen Investments Limited, purchased an aggregate of 1,387,925 of the Company’s Class A Ordinary Shares at $2.882 per share, representing 10% premium to the last closing price.

On March 26, 2021, Aptorum Group entered into a Sales Agreement with H.C. Wainwright & Co., LLC, acting as the Company’s sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, Class A Ordinary Shares for an aggregate offering price of up to $15,000,000.

Financial Results for the Six Months Ended June 30, 2021

Aptorum Group reported a net loss of $17.1 million for the six months ended June 30, 2021 compared to $7.0 million for the same period in 2020. The increase in net loss in the current period was driven by loss on investments in marketable securities, net of $7.6 million, and there was a gain on non-marketable investment of $1.6 million in the same period in 2020 while there was no such gain in current period.

Research and development expenses were $5.5 million for the six months ended June 30, 2021 compared to $4.3 million for the same period in 2020. The increase in research and development expenses was mainly due to the increase in services provided by contracted research organizations as a result of our projects’ development.

General and administrative fees were $2.6 million for the six months ended June 30, 2021 compared to $2.1 million for the same period in 2020. The increase in general and administration fees was mainly due to a one-off reversal of over-provision in relations to bonus payables to our directors, employees, external consultants and advisors in the last period. It was partly offset by the decrease in travelling expenses due to the outspread of COVID-19 and the decrease in amortization and depreciation due to the disposal of fixed assets in the second half of 2020.

Legal and professional fees were $1.2 million for the six months ended June 30, 2021 compared to $1.5 million for the same period in 2020. The decrease in legal and professional fees was mainly due to the decrease in consultancy services during current period.

As of June 30, 2021, cash and restricted cash totalled approximately $20.1 million and total equity was approximately $26.5 million.

Aptorum Group expects that its existing cash and restricted cash together with undrawn line of credit facility from related parties, will enable it to fund its operating and capital expenditure requirements for at least the next 12 months.

APTORUM GROUP LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Stated in U.S. Dollars)

		June 30, 2021				December 31, 2020
		(Unaudited)
ASSETS
Current assets:
Cash		$	19,935,888			$	3,495,231
Restricted cash			130,125				130,125
Digital currencies			–				1,539
Accounts receivable			47,093				62,221
Inventories			32,785				39,133
Marketable securities, at fair value			702,937				28,384,944
Investments in derivatives			–				4,289
Amounts due from related parties			113,858				–
Due from brokers			160,341				160,337
Other receivables and prepayments			795,087				1,378,996
Total current assets			21,918,114				33,656,815
Property, plant and equipment, net			4,148,449				4,686,323
Operating lease right-of-use assets			355,202				547,389
Non-marketable investments			4,079,707				4,079,707
Intangible assets, net			917,170				964,857
Long-term deposits			296,225				296,225
Total Assets		$	31,714,867			$	44,231,316
LIABILITIES AND EQUITY
LIABILITIES
Current liabilities:
Amounts due to related parties		$	133,761			$	145,926
Accounts payable and accrued expenses			3,537,237				3,240,772
Finance lease liabilities, current			50,881				49,396
Operating lease liabilities, current			339,040				432,600
Total current liabilities			4,060,919				3,868,694
Finance lease liabilities, non-current			22,106				47,923
Operating lease liabilities, non-current			63,008				155,121
Loan payables to related parties			1,098,492				2,007,285
Total Liabilities		$	5,244,525			$	6,079,023
Commitments and contingencies			–				–
EQUITY
Class A Ordinary Shares ($1.00 par value; 60,000,000 shares authorized, 13,170,374 and 11,584,324 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively)		$	13,170,374			$	11,584,324
Class B Ordinary Shares ($1.00 par value; 40,000,000 shares authorized, 22,437,754 shares issued and outstanding as of June 30, 2021 and December 31, 2020)			22,437,754				22,437,754
Additional paid-in capital			42,441,471				38,247,903
Accumulated other comprehensive income			28,267				53,296
Accumulated deficit			(46,570,550	)			(30,489,126	)
Total equity attributable to the shareholders of Aptorum Group Limited			31,507,316				41,834,151
Non-controlling interests			(5,036,974	)			(3,681,858	)
Total equity			26,470,342				38,152,293
Total Liabilities and Equity		$	31,714,867			$	44,231,316

APTORUM GROUP LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Stated in U.S. Dollars)

		For the six months ended June 30,
		2021				2020
		(Unaudited)				(Unaudited)
Revenue
Healthcare services income		$	637,784			$	327,273
Operating expenses
Costs of healthcare services			(629,987	)			(436,171	)
Research and development expenses			(5,508,356	)			(4,315,033	)
General and administrative fees			(2,564,117	)			(2,076,634	)
Legal and professional fees			(1,240,512	)			(1,540,304	)
Other operating expenses			(189,125	)			(641,457	)
Total operating expenses			(10,132,097	)			(9,009,599	)
Other (loss) income
(Loss) gain on investments in marketable securities, net			(7,565,273	)			192,134
Gain on non-marketable investment			–				1,635,939
Loss on investments in derivatives, net			(4,289	)			(101,233	)
Gain on use of digital currencies			4,918				–
Interest expense, net			(126,102	)			(144,226	)
Sundry income			82,652				111,398
Total other (loss) income, net			(7,608,094	)			1,694,012
Net loss		$	(17,102,407	)		$	(6,988,314	)
Less: net loss attributable to non-controlling interests			(1,020,983	)			(783,749	)
Net loss attributable to Aptorum Group Limited		$	(16,081,424	)		$	(6,204,565	)
Net loss per share – basic and diluted		$	(0.47	)		$	(0.21	)
Weighted-average shares outstanding – basic and diluted			34,280,137				29,956,393
Net loss		$	(17,102,407	)		$	(6,988,314	)
Other Comprehensive (loss) income
Exchange differences on translation of foreign operations			(25,029	)			31,170
Other Comprehensive (loss) income			(25,029	)			31,170
Comprehensive loss			(17,127,436	)			(6,957,144	)
Less: comprehensive loss attributable to non-controlling interests			(1,020,983	)			(783,751	)
Comprehensive loss attributable to the shareholders of Aptorum Group Limited			(16,106,453	)			(6,173,393	)

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.

These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided “as is” without any representation or warranty of any kind.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005596/en/

Aptorum Group Limited

Investor Relations Department

[email protected]

+44 20 80929299

Redchip – Financial Communications United States

Investor relations

Dave Gentry

[email protected]

+1 407 491 4498

Actifin – Financial Communications Europe

Investor relations

Ghislaine Gasparetto

[email protected]

+33 1 56 88 11 22

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Infectious Diseases Biotechnology Health Oncology

MEDIA:

Logo

The Brew Kettle Brewery and Restaurant to Open at the Hall of Fame Village Powered by Johnson Controls

CANTON, Ohio–(BUSINESS WIRE)–
Hall of Fame Resort & Entertainment Company (“HOFV” or the “Company”) (NASDAQ: HOFV, HOFVW), the only resort, entertainment and media company centered around the power of professional football and owner of the Hall of Fame Village powered by Johnson Controls (the “Destination”), today announced that The Brew Kettle, an Ohio-based brewery and restaurant that has been producing award-winning craft beers since 1995, will be opening a new location at the Destination. The Brew Kettle will be connected to the previously announced Topgolf Swing Suite facility at the Retail Promenade of the Hall of Fame Village.

“We are thrilled to welcome The Brew Kettle, one of the most well-respected breweries in the great state of Ohio, to the Hall of Fame Village campus,” stated Mike Levy, President of Operations for HOFV. “Our guests will now have yet another excellent dining and beverage option when they visit, whether it’s for one of our sporting or concert events or just leisurely enjoying all the Destination has to offer. We look forward to a long and mutually beneficial relationship that will offer our guests a wide variety of craft beers, high-quality food, and fantastic entertainment from one of Ohio’s best franchises.”

The Brew Kettle space will offer food, beverages, and entertainment for all ages, and will include a more than 4,000-square-foot patio overlooking Tom Benson Hall of Fame Stadium. The nearby Topgolf Swing Suite player bays, which are powered by industry-leading Full Swing Golf simulators, will feature signature Topgolf games and virtual golf experiences, as well as football, baseball, hockey, zombie dodgeball, and much more.

“The Brew Kettle is very excited about partnering with the Hall of Fame Village. This is a tremendous opportunity for us to help promote the many initiatives that are set to open in the new Village and grow our footprint of brands in Ohio,” said Bryan Weber and Chris Russo, Partners of The Brew Kettle. “The Brew Kettle family looks forward to opening its newest Pub and Smokehouse in the Village along with all its award-winning craft beers like White Rajah, Major Lager, Big Woodie, as well as a Hall of Fame Village-inspired craft beer. With the addition of the Topgolf Swing Suites in our new Pub there will be plenty of great gatherings with new and old friends here in Canton.”

The Brew Kettle has expanded numerous times over the years to meet the demands of its customers and spans four additional locations throughout Ohio in addition to its production facility. The brewery’s mission has always been to brew consistently stellar beer while offering a host of options including year-round, seasonal, specialty and one-off options.

The Brew Kettle joins other prominent retail establishments that will reside at the Destination, including Shula’s Restaurant Group and Esports Entertainment Group. The Brew Kettle also operates four other locations including Hudson, Mentor, Amherst and its original Pub and Brew on Premise location in Strongsville.

About the Hall of Fame Resort & Entertainment Company

The Hall of Fame Resort & Entertainment Company (NASDAQ: HOFV, HOFVW) is a resort and entertainment company leveraging the power and popularity of professional football and its legendary players in partnership with the Pro Football Hall of Fame. Headquartered in Canton, Ohio, the Hall of Fame Resort & Entertainment Company is the owner of the Hall of Fame Village powered by Johnson Controls, a multi-use sports, entertainment and media destination centered around the Pro Football Hall of Fame’s campus. Additional information on the Company can be found at www.HOFREco.com.

Forward-Looking Statements

Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words and phrases such as “opportunity,” “future,” “will,” “goal,” and “look forward” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the inability to recognize the anticipated benefits of the business combination; costs related to the business combination; the inability to maintain the listing of the Company’s shares on Nasdaq; the Company’s ability to manage growth; the Company’s ability to execute its business plan and meet its projections, including refinancing its existing term loan and obtaining financing to construct planned facilities; potential litigation involving the Company; changes in applicable laws or regulations; general economic and market conditions impacting demand for the Company’s products and services, and in particular economic and market conditions in the resort and entertainment industry; the potential adverse effects of the ongoing global coronavirus (COVID-19) pandemic on capital markets, general economic conditions, unemployment and the Company’s liquidity, operations and personnel, as well as those risks and uncertainties discussed from time to time in our reports and other public filings with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005567/en/

Media Inquiries

[email protected]

Investor Inquiries

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Retail General Sports Entertainment Lodging Destinations Travel Commercial Building & Real Estate Restaurant/Bar General Entertainment Construction & Property Sports Vacation Wine & Spirits Food/Beverage

MEDIA:

Logo